Clinical Monograph: Ozempic 1 mg (Semaglutide)

Ozempic 1 mg pre-filled pen packaging. Source: Buy Super Specialty Medicines for Cancer, HIV & Kidney Care at …

1. Classification and Chemical Overview

Semaglutide is a recombinant human glucagon-like peptide-1 (GLP-1) receptor agonist produced by recombinant DNA technology in Saccharomyces cerevisiae. Chemically, it features 94% structural homology to native human GLP-1 (7-37), modified with an amino acid substitution at position 8 (alanine to $\alpha$-aminobutyric acid) to impart resistance to degradation by dipeptidyl peptidase-4 (DPP-4), and a C18 fatty diacid spacer conjugated to lysine at position 26 to facilitate albumin binding.

Under the Anatomical Therapeutic Chemical (ATC) classification system, semaglutide is indexed under A10BJ06. In most global regulatory jurisdictions, Ozempic is classified as a Prescription Only Medicine (POM).

2. Mechanism of Action and Pharmacodynamics

Semaglutide acts as a selective GLP-1 receptor agonist that binds to and activates GLP-1 receptors present in pancreatic $\beta$-cells, brain, gastrointestinal tract, and cardiovascular system:

• Glucose-Dependent Insulin Secretion: Stimulates insulin secretion from pancreatic $\beta$-cells in a glucose-dependent manner, suppressing elevated blood glucose levels without inducing hypoglycemia when used as monotherapy.

• Glucagon Suppression: Decreases inappropriate glucagon secretion from pancreatic $\alpha$-cells during hyperglycemic or euglycemic states.

• Gastric Emptying Delay: Slows gastric emptying rate in the early postprandial phase, reducing the rate of systemic glucose absorption.

• Central Appetite Regulation: Crosses blood-brain barrier structures to act on central neural circuits (e.g., arcuate nucleus of the hypothalamus), increasing satiety and reducing energy intake.

3. Approved Clinical Indications and Dosing Scope

Licensing for Ozempic 1 mg includes:

• Type 2 Diabetes Mellitus: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

• Cardiovascular Risk Reduction: Reduction in the risk of major adverse cardiovascular events (MACE; cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease.

Dosing & Administration Regimen:

• Weekly Dosing: Administered once weekly on the same day each week, any time of day, with or without food.

• Dose Escalation: Treatment begins at 0.25 mg weekly for 4 weeks (initiation dose, non-therapeutic for glycemic control), increased to 0.5 mg weekly for at least 4 weeks. If additional glycemic control is required, the dose is escalated to the maintenance strength of 1 mg weekly (with a maximum dose of 2 mg weekly if needed).

• Administration Site: Subcutaneous injection into the abdomen, thigh, or upper arm.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Absolute bioavailability is approximately 89%. Peak plasma concentrations (Cmax​) occur between 1 and 3 days (Tmax​) post-injection. Steady-state exposure is reached following 4 to 5 weeks of once-weekly administration.

• Distribution: Extensively bound to plasma albumin (> 99%). Volume of distribution (Vd​) is approximately 12.5 L.

• Biotransformation: Primary metabolic clearance occurs via proteolytic cleavage of the peptide backbone and sequential $\beta$-oxidation of the fatty acid side-chain. Semaglutide is not cleared via specific organ-based hepatic CYP pathways.

• Elimination: Metabolites are excreted via urine and feces. Elimination half-life (t1/2​) is approximately 1 week (7 days), permitting once-weekly subcutaneous administration.

5. Physiological Effects and Adverse Event Spectrum

Semaglutide regulates systemic glucose homeostasis, delays gastrointestinal motility, and alters appetite signaling.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Nausea, diarrhea, hypoglycemia (when co-administered with sulfonylureas or insulin).

• Common ($\ge 1/100$ to $<1/10$): Vomiting, abdominal pain, abdominal distension, constipation, dyspepsia, gastritis, gastroesophageal reflux disease (GERD), eructation, flatulence, fatigue, cholelithiasis, increased lipase/amylase.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Dysgeusia, elevated heart rate, acute pancreatitis, delayed gastric emptying, injection site reactions, hypersensitivity.

• Rare (<1/1,000): Anaphylactic reactions, angioedema.

6. Contraindications, Drug Interactions, and Clinical Precautions

Kontraindikationen

• Personal or family history of Medullary Thyroid Carcinoma (MTC).

• Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

• Known hypersensitivity to semaglutide or any formulation excipients.

Key Drug Interactions

• Delayed Gastric Emptying Impact: Slows gastric transit time, which may alter the rate and extent of absorption of concomitantly administered oral medications (especially drugs with narrow therapeutic indices).

• Insulin Secretagogues & Insulin: Concurrent administration with insulin or sulfonylureas increases the risk of severe hypoglycemia. Dose reductions of the secretagogue or insulin may be required.

Clinical Precautions and Monitoring

• Boxed Warning (Thyroid C-Cell Tumors): In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors. Counsel patients regarding symptoms of thyroid tumors (e.g., neck mass, dysphagia, dyspnea, persistent hoarseness).

• Pancreatitis: Acute pancreatitis has been reported. Discontinue immediately if pancreatitis is suspected.

• Diabetic Retinopathy Complications: Rapid improvements in glucose control have been associated with a temporary worsening of diabetic retinopathy; monitor patients with a history of retinopathy.

• Acute Kidney Injury: Dehydration secondary to severe gastrointestinal adverse reactions can cause acute renal failure or worsening of chronic renal failure. Encourage adequate fluid intake.